- Home
- BGC vs RYTM Comparison
BGC vs RYTM Comparison
Compare BGC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGC
- RYTM
- Stock Information
- Founded
- BGC 1945
- RYTM 2008
- Country
- BGC United States
- RYTM United States
- Employees
- BGC N/A
- RYTM N/A
- Industry
- BGC Investment Bankers/Brokers/Service
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- BGC Finance
- RYTM Health Care
- Exchange
- BGC Nasdaq
- RYTM Nasdaq
- Market Cap
- BGC 4.3B
- RYTM 4.3B
- IPO Year
- BGC 1999
- RYTM 2017
- Fundamental
- Price
- BGC $10.41
- RYTM $89.15
- Analyst Decision
- BGC Strong Buy
- RYTM Strong Buy
- Analyst Count
- BGC 2
- RYTM 13
- Target Price
- BGC $14.50
- RYTM $88.77
- AVG Volume (30 Days)
- BGC 3.4M
- RYTM 955.3K
- Earning Date
- BGC 07-31-2025
- RYTM 08-05-2025
- Dividend Yield
- BGC 0.77%
- RYTM N/A
- EPS Growth
- BGC 128.63
- RYTM N/A
- EPS
- BGC 0.27
- RYTM N/A
- Revenue
- BGC $2,252,851,000.00
- RYTM $136,863,000.00
- Revenue This Year
- BGC $35.79
- RYTM $37.56
- Revenue Next Year
- BGC $9.83
- RYTM $74.99
- P/E Ratio
- BGC $39.21
- RYTM N/A
- Revenue Growth
- BGC 13.24
- RYTM 48.88
- 52 Week Low
- BGC $7.24
- RYTM $40.61
- 52 Week High
- BGC $11.79
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- BGC 59.99
- RYTM 78.49
- Support Level
- BGC $10.21
- RYTM $86.25
- Resistance Level
- BGC $10.96
- RYTM $94.80
- Average True Range (ATR)
- BGC 0.28
- RYTM 3.58
- MACD
- BGC -0.00
- RYTM 2.88
- Stochastic Oscillator
- BGC 64.05
- RYTM 83.38
About BGC BGC Group Inc.
BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.